VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 300 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2017. The put-call ratio across all filers is 2.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2018 | $7,960,000 | +538.3% | 500,000 | +733.3% | 0.03% | +560.0% |
Q4 2017 | $1,247,000 | -97.5% | 60,000 | -98.3% | 0.01% | -97.8% |
Q3 2017 | $50,155,000 | +5698.3% | 3,500,000 | +6900.0% | 0.22% | +4380.0% |
Q2 2017 | $865,000 | -78.2% | 50,000 | -86.1% | 0.01% | -77.3% |
Q1 2017 | $3,960,000 | -79.3% | 359,000 | -72.8% | 0.02% | -83.6% |
Q4 2016 | $19,166,000 | -87.1% | 1,320,000 | -78.2% | 0.13% | -87.2% |
Q3 2016 | $148,560,000 | +40.1% | 6,051,300 | +14.9% | 1.04% | +44.9% |
Q2 2016 | $106,025,000 | -1.8% | 5,264,400 | +28.3% | 0.72% | -12.9% |
Q1 2016 | $107,948,000 | +5831.2% | 4,104,500 | +22830.2% | 0.83% | +5420.0% |
Q4 2015 | $1,820,000 | -80.9% | 17,900 | -58.3% | 0.02% | -77.3% |
Q2 2015 | $9,530,000 | -49.7% | 42,900 | -67.6% | 0.07% | -50.4% |
Q4 2014 | $18,933,000 | -90.9% | 132,300 | -91.6% | 0.13% | -91.5% |
Q3 2014 | $207,309,000 | +7.5% | 1,580,100 | +3.4% | 1.56% | +26.2% |
Q2 2014 | $192,788,000 | – | 1,528,606 | – | 1.24% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |